IP Library Granted Patent US 7,906,492
Granted Patent B2
US 7,906,492 · App. 11/334,763 · Granted Mar 15, 2011

Therapy-enhancing glucan

Assignee: Sloan-Kettering Institute for Cancer Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,906,492
App. No.
11/334,763
Granted
Mar 15, 2011
Kind
B2
Abstract

A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal, and at least one antibody for the cancer. A method of treating cancer in a mammal is also disclosed. The method comprises administering a suitable orally administered glucan and at least one antibody for the treatment of cancer to the mammal. In addition a composition for delivery of peptide, protein, RNA, DNA or plasmid comprising effective amount of a beta-glucan is disclosed.

Claims (12)

1. A delivery composition comprising an isolated DNA, RNA or plasmid and an effective amount of a barley β-glucan for delivery of said DNA, RNA or plasmid into cells, wherein said β-glucan is not encapsulated, and has an average molecular weight of about 15 to about 350 kD.

2. The composition of claim 1 , wherein the glucan comprises β-1,4 bonds in the backbone.

3. The composition of claim 2 , wherein the glucan further comprises β-1,3 bonds in the backbone.

4. The composition of claim 1 , wherein the glucan comprises β-1,3 bonds in the backbone.

5. The composition of claim 1 wherein the glucan is a particulate or soluble glucan.

6. The composition of claim 1 wherein the composition is formulated for oral administration.

7. A composition for delivering a DNA, RNA or plasmid into a cell consisting essentially of said DNA, RNA or plasmid, and an effective amount of a barley β-glucan, wherein said β-glucan has an average molecular weight of about 15 to about 350 kD.

8. The composition of claim 7 , wherein the glucan comprises β-1,4 bonds in the backbone.

9. The composition of claim 8 , wherein the glucan further comprises β-1,3 bonds in the backbone.

10. The composition of claim 7 , wherein the glucan comprises β-1,3 bonds in the backbone.

11. The composition of claim 7 , wherein the glucan is a particulate or soluble glucan.

12. The composition of claim 7 , wherein the composition is formulated for oral administration.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2006
From: CHEUNG, NAI-KONG V.
To: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
Reel/Frame 017481/0231 →
Continuity (8)
Continuation In Part 11218044 · Aug 31, 2005
Continuation 10621027 · Jul 16, 2003
Continuation In Part PCTUS0201276 · Jan 15, 2002
Continuation In Part 11334763
Continuation In Part PCTUS2004023099 · Jul 16, 2004
Continuation In Part 10621027 · Jul 16, 2003
Provisional Application 60261911 · Jan 16, 2001
Related Publication 20060160766A1 · Jul 20, 2006